AVB-001 pleural / Avenge Bio - LARVOL DELTA

Avenge Bio Receives Positive Feedback from Pre-IND FDA Meeting on Development Path for AVB-001 Mesothelioma Program and Provides Pipeline Update (PRNewswire) - "Avenge Bio, Inc...today announced that it completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ('FDA') with respect to AVB-001 for the treatment of pleural malignant mesothelioma, and provided a corporate update."

FDA event • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Solid Tumor